How to use Technologies offered

A search for a cancer, preclinical stage, synthetic opportunity would use the selection "Therapeutics, Diagnostics" in 'Sector', 'Cancerous, neoplasmatic' in 'Disease Category', 'Drugs, Small Molecule' in 'Technology' and 'Preclinical' in 'Development Stage'.

Selection of 'Enabling Technology, Platform Technology' in 'Sector' will identify all kinds of research technologies that can be used in more areas of life sciences than pharmaceuticals only.

Each technology profile gives the name of a company or academic institute as source of the offer, and a link allowing to contact the potential licensor. In most cases a profile includes a pdf covering the available non-confidential information as well as detailed contact data.

Registered users can create non-public notifications profiles which will inform them about new 'Technologies Offered' entries fitting their needs as specified. In addition these profiles allow them to filter the available information more comfortably.


CEACAM1 antibodies for anti-viral therapy

Organization name

PROvendis GmbH



Cytotoxic CD8-positive T cells
constitute the crucial leukocyte subpopulation for a cellular response against viral infection. Since only very few direct anti-viral therapeutics are available, the stimulation of an efficient and specific immune response against a viral infection is a valid alternative or additional therapeutic approach. The first of such strategies has been established by use of high doses of interferon, which however has a high risk of adverse reactions of the immune system, and low response rates. Therefore, it is mandatory to search for further immune stimulatory strategies that more specifically induce an anti-viral T cell repsonse.

The herein described approach is based on a antibody-mediated stimulation of the carcino-embryonic antigen-related cell adhesion molecule 1 (CEACAM1), which activates early parts of both the B cell and T cell receptor-induced signal transduction.

The researchers have shown on the example of the lymphocytic choriomeningitis virus (LCMV) that these antibodies stimulate the activation and expansion of virus specific cytotoxic T cells, which comes along with a reduced virus load in serum and organs of mice. In vitro studies confirmed efficacy also against influenza virus and cytomegalovirus.

Commercial Opportunities

The monoclonal, humanized anti-CEACAM1 antibodies are offered for licensing and further therapeutic development.

Competitive Advantages

  • Complementary anti-viral therapy Option
  • Applies to a broad range of viruses
  • Specific immune response against specific viruses

Current Status

The researcher have conducted experiments with a LMCV-specific immune response mouse model. Further proof of principle with the humanized variant of the antibody has been provided by means of humanized CEACAM1 mice. The antibody activates human virus-specific CD8+ T cells in vitro.

In case of interest we are pleased to inform you about the patent status.

Relevant Publications

Khairnar, V., et al. (2015) CEACAM1 induces B-cell survival and is essential for protective antiviral antibody production. Nature Communications 6: 6217.

To view the contact information, attachments and url of this profile you have to login into your account or register a new account: Login Register

Your feedback

Please click here to log in to view the complete profile.


latest entries